Targeting MAD2B as a strategy for ischemic stroke therapy
Open Access
- 5 July 2024
- journal article
- research article
- Published by Elsevier in Journal of Advanced Research
- Vol. 72, 369-385
Abstract
No abstract availableKeywords
Funding Information
- Huazhong University of Science and Technology
- National Natural Science Foundation of China (81974162)
- National Natural Science Foundation of China (81671066)
This publication has 58 references indexed in Scilit:
- Tetrahydropyridine LIMK inhibitors: Structure activity studies and biological characterizationEuropean Journal of Medicinal Chemistry, 2024
- Sulforaphane promotes white matter plasticity and improves long-term neurological outcomes after ischemic stroke via the Nrf2 pathwayFree Radical Biology and Medicine, 2022
- Modulation of hippocampal plasticity in learning and memoryCurrent Opinion in Neurobiology, 2022
- Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP‐43 pathologyClinical and Translational Medicine, 2021
- The Rho kinase 2 (ROCK2)-specific inhibitor KD025 ameliorates the development of pulmonary arterial hypertensionBiochemical and Biophysical Research Communications, 2021
- Epimedium flavonoids improve cognitive impairment and white matter lesions induced by chronic cerebral hypoperfusion through inhibiting the Lingo-1/Fyn/ROCK pathway and activating the BDNF/NRG1/PI3K pathway in ratsBrain Research, 2020
- Post-Stroke Cognitive Impairment: A Review Focusing on Molecular BiomarkersJournal of Molecular Neuroscience, 2020
- Comparative Study of ROCK1 and ROCK2 in Hippocampal Spine Formation and Synaptic FunctionNeuroscience Bulletin, 2019
- MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradationMolecular Oncology, 2018
- SelectiveROCK2 inhibition in focal cerebral ischemiaAnnals of Clinical and Translational Neurology, 2013